A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Either Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) or Advanced or Metastatic Soft Tissue Sarcomas (STS).

Trial Profile

A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Either Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) or Advanced or Metastatic Soft Tissue Sarcomas (STS).

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2014

At a glance

  • Drugs Retaspimycin (Primary)
  • Indications Gastrointestinal stromal tumours; Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 05 Jan 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 05 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jun 2008 Results presented at the Annual Meeting of the American Society of Clinical Oncology 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top